From our survey
Myths caregivers hear when depression outlasts the medication
When depression hangs on through one medication and then another, the people closest to it start to form beliefs. Some are comforting. Some are frightening. Many are simply not true, and they can quietly keep a family from the next step.
This myth-check is for caregivers in St. Charles County whose loved one's depression has not responded to standard medication. It tests seven common beliefs against general medical facts and against what 443 Midwest adults told our survey, using top-line figures that are now final.
Myth one: "This is rare. Most people get better on the first try."
Seventy-two percent of our respondents had run into depression, anxiety, or PTSD that stayed heavy despite standard medication, personally or through someone close. It was their own experience for 37 percent, someone close for 22 percent, and both for 13 percent.
That question measured experience, not a formal diagnosis. Still, it tells you something about your neighbors in O'Fallon, St. Peters, and Wentzville. The frustration you are living with is widely shared, even if few people talk about it at the kitchen table.
Myth two: "If the medications did not work, nothing will."
This is the most painful belief, and it is not supported. Clinicians generally describe depression that has not improved after more than one adequate trial of antidepressants as treatment-resistant. The term describes a history, not a ceiling. Other approaches exist precisely because the first ones do not work for everyone.
Those approaches can include changing or combining medications, psychotherapy, TMS, esketamine, and, for some people with severe depression, electroconvulsive therapy. Which of these fits is a clinical question. The key point is that the list does not end at the second prescription.
Myth three: "They are just not trying hard enough."
Families sometimes land here out of exhaustion. It is understandable, and it is wrong. Whether a medication works depends on biology and circumstances, not willpower. A person who has taken their medication as prescribed and still feels hollow has not failed. The treatment has not fit yet.
Myth four: "The next step is always another pill."
Sometimes a medication change is exactly right. But it is not the only path, and many people prefer to hear about others. Sixty-four percent of our respondents put value on a drug-free path, even though most did not know what TMS was.
Newer options are also widely unfamiliar. Ask a room of Midwest adults about Spravato, an FDA-approved esketamine spray used when depression resists treatment, and 73 percent will say the name means nothing to them. If nobody has mentioned options beyond another prescription, a fair question is: "What else is there when medication has not been enough?"
Myth five: "Ketamine therapy means taking ketamine at home."
Ads have blurred this. There are three distinct things:
- Esketamine nasal spray, the approved version for depression that resists treatment, available only at certified clinics, where patients stay for observation and then need a ride home.
- IV ketamine, used off-label for depression at infusion clinics.
- At-home ketamine, prescribed through telehealth and taken without a clinician present.
Most of our respondents preferred a clinic somewhere in the process. Forty-four percent chose in-person care, and 23 percent chose a clinic start with care later moving home, 67 percent combined. If a loved one is interested, asking which of the three a provider means is a fair and important question. For the approved option, a plain guide to Spravato explains what to expect.
Myth six: "Insurance will never cover newer treatments, so why ask?"
Coverage varies by plan and treatment, and asking is the only way to find out. Do not rule it out in advance. Coverage mattered more than anything else to our respondents, a top-two provider factor for 85 percent. Just over half would also put up with extra insurance steps, such as prior authorization, instead of self-paying for an easier road.
For St. Charles County families, that means calling the plan, whether MO HealthNet, a commercial carrier, Medicare, or TRICARE, and asking directly: Is this covered? Is approval required? Which clinics near us are in network?
Myth seven: "There is nothing a caregiver can do."
You cannot make treatment work, and you cannot make decisions for another adult. But your influence is real. A close friend or relative was the voice 18 percent said would most push them to try a newer treatment. Only one source outranked family, the person's own doctor, at 74 percent.
Practical things you can do:
- List each medication, its dose, how many weeks it lasted, and the outcome. A doctor weighing the treatment-resistant label will want exactly that.
- Offer to book a dedicated appointment, and to come along if your loved one wants you there.
- Look into coverage before the appointment so the conversation does not stall on cost.
- Plan transportation. Forty-three percent of respondents made nearness a top-two factor, and some treatments require frequent visits and a ride home. A clinic in the county may be easier than one across the river.
A truth to hold onto
Depression that has not responded yet is a reason to ask new questions, not to stop asking. Most people in our survey would start that conversation with their primary care doctor, 56 percent of them. You can help your loved one get there.
If you are worried about safety
If your loved one has mentioned suicide, or you are afraid for their safety, act now. Staff at the Suicide and Crisis Lifeline answer around the clock, and you can reach out for someone else. Text or call 988, where veterans can press 1, and call 911 if danger is immediate.
Limits
This article combines survey findings with general information. It is not medical advice and does not suggest any specific treatment will help. A clinician who knows your loved one should guide the decisions.
Methodology
Our publisher both commissioned this study and paid for it. It ran with Pollfish, on that company's consumer panel, until June 23, 2026, drawing 443 adults aged 18 to 64 from Wisconsin, Oklahoma, Missouri, Kansas, Minnesota, Illinois, Ohio, Iowa, Nebraska, and Indiana. The experience question captured personal or close experience, not diagnosis. We report ten-state top-line figures only, with no county breakout, all from the final, validated dataset.